CorrespondenceOsilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence – Authors' reply
References (7)
- et al.
Consensus on diagnosis and management of Cushing's disease: a guideline update
Lancet Diabetes Endocrinol
(2021) - et al.
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial
Lancet Diabetes Endocrinol
(2019) - et al.
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase
Lancet Diabetes Endocrinol
(2020)
There are more references available in the full text version of this article.
Cited by (4)
Validation of criteria for defining Pituitary Tumors Centers of Excellence (PTCOE)
2023, Research SquarePituitary tumor centers of excellence for Cushing’s disease
2022, Pituitary
© 2022 Elsevier Ltd. All rights reserved.